Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

9.44
+0.61006.91%
Pre-market: 9.460.0200+0.21%04:37 EDT
Volume:27.29M
Turnover:263.21M
Market Cap:10.00B
PE:-9.55
High:10.09
Open:8.92
Low:8.90
Close:8.83
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:2.87
T/O Rate:6.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-9.56
PE(LYR):-24.71

Loading ...

ImmunityBio price target lowered to $12 from $13 at BTIG

TIPRANKS
·
May 08

ImmunityBio (IBRX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 08

ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum

Benzinga Earnings
·
May 08

UPDATE: ImmunityBio Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate

Benzinga Earnings
·
May 07

ImmunityBio faces securities class action after FDA flags misleading promotions; shares fall 21%

Reuters
·
May 07

ImmunityBio Q1 net loss widens to $632.8 million; revenue more than doubled to $44.2 million

Reuters
·
May 07

Immunitybio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7X Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

THOMSON REUTERS
·
May 07

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 06

ImmunityBio presents new ANKTIVA+BCG comparative data in NMIBC CIS at AUA 2026

Reuters
·
May 05

A Look At ImmunityBio (IBRX) Valuation As ANKTIVA Rollout Drives Rapid Product Revenue Growth

Simply Wall St.
·
May 03

ImmunityBio faces shareholder class action over alleged ANKTIVA promotion misstatements

Reuters
·
Apr 30

ImmunityBio announces annual shareholder meeting

Reuters
·
Apr 30

H.C. Wainwright Sticks to Its Buy Rating for ImmunityBio (IBRX)

TIPRANKS
·
Apr 30

Does ImmunityBio (IBRX) Expanding ANKTIVA to Saudi Arabia Redefine Its Global Oncology Strategy?

Simply Wall St.
·
Apr 28

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 21

ImmunityBio announces availability of ANKTIVA in Saudi Arabia

TIPRANKS
·
Apr 21

ImmunityBio launches ANKTIVA in Saudi Arabia, expanding Middle East presence

Reuters
·
Apr 21

Immunitybio Announces Anktiva® Is NOW Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of Mena Partnership

THOMSON REUTERS
·
Apr 21

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Apr 21

ImmunityBio hit with securities class action over ANKTIVA promotion claims

Reuters
·
Apr 16